| Approved Therapies | 3 |
|---|
| Companies in Development | 8+ |
|---|
| Phase 3 Trials | 2 |
|---|
| Mechanism | AChE inhibition, cholinergic modulation |
|---|
Cholinergic therapies for Alzheimer's disease target the cholinergic system, which is significantly impaired in AD due to degeneration of basal forebrain cholinergic neurons. The primary approach involves acetylcholinesterase (AChE) inhibition to increase synaptic acetylcholine levels, compensating for lost cholinergic signaling.
The cholinergic hypothesis of AD, proposed in the 1970s, remains clinically validated with three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) representing the standard of care for symptomatic cognitive benefits.
Company: Eisai (co-developed with Pfizer)
- First approved in 1996 for mild-to-moderate AD
- Once-daily oral formulation
- Selective AChE inhibitor with minimal GI side effects
- Available in 5mg, 10mg, and 23mg (Aricept 23mg for severe AD) doses
Company: Novartis
- Approved in 2000 for mild-to-moderate AD
- Twice-daily oral and once-daily patch formulations
- Dual AChE and butyrylcholinesterase (BuChE) inhibitor
- Particularly effective in patients with more advanced disease (higher BuChE activity)
Company: Janssen (Johnson & Johnson)
- Approved in 2001 for mild-to-moderate AD
- Allosteric modulator of nicotinic receptors in addition to AChE inhibition
- Once-daily extended-release formulation available
- May provide additional benefits through nicotinic receptor activation
| Company |
Compound |
Stage |
Mechanism |
| Axsome Therapeutics |
AXS-05 (dextromethorphan/bupropion) |
Phase 3 |
NMDA antagonist + norepinephrine/dopamine reuptake |
| Labyrinth Holdings |
AChE modulators |
Preclinical |
Novel AChE targeting |
| Cerenis Therapeutics |
CER-001 |
Phase 2 |
HDL mimetic, may support cholinergic function |
| Company |
Compound |
Stage |
Target |
| Excelsior Neuroscience |
EXS-001 |
Phase 1 |
Muscarinic M1 agonist |
| Lucid Neuroscience |
LUC-201 |
Preclinical |
α7-nicotinic receptor modulator |
| Otsuka Pharmaceuticals |
n.b. |
Discovery |
M1 positive allosteric modulator |
Several companies are developing combination therapies that include cholinergic mechanisms:
- AB Science - Masitinib (tyrosine kinase inhibitor) + AChE inhibitors - Phase 3 in AD
- Cognition Therapeutics - CT-1812 (sigma-2 receptor antagonist) with cholinergic signaling - Phase 2
- Neurodegeneration Pipeline - Multi-target approaches combining AChE inhibition with other mechanisms
¶ Market Landscape
The global AD cholinergic therapy market is valued at approximately $4-5 billion annually, with donepezil being the most widely prescribed. Key market trends include:
- Patent expirations driving generic competition
- Focus on disease modification shifting investment away from symptomatic treatments
- Combination therapy development as companies seek to enhance efficacy
- Novel delivery systems (transdermal patches, nanoparticles) improving patient compliance
flowchart TD
A["Cholinergic Therapy Development"] --> B["FDA-Approved"]
A --> C["In Development"]
B --> B1["Donepezil - Eisai"]
B --> B2["Rivastigmine - Novartis"]
B --> B3["Galantamine - Janssen"]
C --> C1["Phase 3: 2 compounds"]
C --> C2["Phase 2: 4 compounds"]
C --> C3["Phase 1: 3 compounds"]
C --> C4["Preclinical: 5+ compounds"]
C1 --> C1a["Axsome AXS-05"]
C1 --> C1b["AB Science Masitinib"]